Colorectal signet-ring cell carcinoma: Benefit from adjuvant chemotherapy but a poor prognostic factor

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 333-339

  Hugen, Niek ^a   Verhoeven, Rob H ^b   Lemmens, Valery E ^b,c   Van Aart, Carola J ^a   Elferink, Marloes A ^d   Radema, Sandra A ^a   Nagtegaal, Iris D ^a   De Wilt, Johannes H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Department of Research and Registration   (Netherlands)

Author keywords

adjuvant chemotherapy; colorectal cancer; epidemiology; mucinous carcinoma; signet ring cell carcinoma

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNET RING CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TUMOR LOCALIZATION; ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADJUVANT CHEMOTHERAPY; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; EPIDEMIOLOGY; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NETHERLANDS; PROGNOSIS;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PROGNOSIS; SURVIVAL RATE;

EID: 84920975707     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28981     Document Type: Article

References (23)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Weitz J, Koch M, Debus J, et al., Colorectal cancer. Lancet 2005; 365: 153-65.
3. Hyngstrom JR, Hu CY, Xing Y, et al., Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol 2012; 19: 2814-21.
4. Bosman FT, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of the digestive system, 4th ed. Lyon: International Agency for Research on Cancer, 2010.
5. Du W, Mah JT, Lee J, et al., Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum 2004; 47: 78-85.
6. Hugen N, Verhoeven RH, Radema SA, et al., Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. Ann Oncol 2013; 24: 2819-2824.
7. Chew MH, Yeo SA, Ng ZP, et al., Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers. Int J Colorectal Dis 2010; 25: 1221-1229.
8. Song W, Wu SJ, He YL, et al., Clinicopathologic features and survival of patients with colorectal mucinous, signet-ring cell or non-mucinous adenocarcinoma: experience at an institution in southern China. Chin Med J (Engl) 2009; 122: 1486-1491.
9. Lee WS, Chun HK, Lee WY, et al., Treatment outcomes in patients with signet ring cell carcinoma of the colorectum. Am J Surg 2007; 194: 294-298.
10. Chen JS, Hsieh PS, Hung SY, et al., Clinical significance of signet ring cell rectal carcinoma. Int J Colorectal Dis 2004; 19: 102-107.
11. Chen JS, Hsieh PS, Chiang JM, et al., Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon. Chang Gung Med J 2010; 33: 51-57.
12. Gill S, Loprinzi CL, Sargent DJ, et al., Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797-1806.
13. Compton CC, Fielding LP, Burgart LJ, et al., Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
14. Bittorf B, Merkel S, Matzel KE, et al., Primary signet-ring cell carcinoma of the colorectum. Langenbecks Arch Surg 2004; 389: 178-183.
15. Catalano V, Loupakis F, Graziano F, et al., Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol 2012; 23: 135-141.
16. Hugen N, van de Velde CJ, de Wilt JH, et al., Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol 2014; 25: 651-657.
17. Lemmens VE, Klaver YL, Verwaal VJ, et al., Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011; 128: 2717-2725.
18. Klaver YL, Lemmens VE, Creemers GJ, et al., Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol 2011; 22: 2250-2256.
19. Schouten LJ, Hoppener P, van den Brandt PA, et al., Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993; 22: 369-376.
20. O'Connell MJ, Mailliard JA, Kahn MJ, et al., Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250.
21. Andre T, Boni C, Mounedji-Boudiaf L, et al., Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
22. Laurie JA, Moertel CG, Fleming TR, et al., Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7: 1447-1456.
23. Moertel CG, Fleming TR, Macdonald JS, et al., Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-326.